News Headlines

  1. Cellares And Papillon Therapeutics Partner To Automate Manufacturing Of PPL-001 For Patients With Friedreich's Ataxia 7/21/2026

    Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Papillon Therapeutics Inc., a clinical-stage biotechnology company advancing a pipeline of multi-systemic genetic medicines directed at the underlying causes of inherited disease, today announced a collaboration to automate manufacturing of PPL-001, Papillon’s investigational gene-corrected hematopoietic stem and progenitor cell (HSPC) therapy targeting Friedreich’s ataxia.

  2. Menarini Asia-Pacific And Pharmacosmos Partner To Bring First-In-Class Oncology Supportive Care Therapy Cosela® To Asian Patients 7/21/2026

    Menarini Asia-Pacific today announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela® (trilaciclib) across its Asia-Pacific markets.

  3. Phanes Therapeutics Announces Expansion Of Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate Spevatamig In Combination With KEYTRUDA® (Pembrolizumab) And Chemotherapy For Treatment Of Biliary Tract Cancer 7/21/2026

    Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, has expanded their clinical trial collaboration with Merck (known as MSD outside of the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy in 1L BTC.

  4. Halozyme Announces Global Collaboration And License Agreement With Incyte To Support The Development Of Subcutaneous Formulations Of INCA033989 Using Its ENHANZE® Technology 7/20/2026

    Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology.

  5. Rezon Bio Appoints Dr. Hubert Scholze As Chief Business Officer To Accelerate Global Commercial Expansion 7/20/2026
  6. Samsung Biologics Announces All-Cash Offer To Acquire PolyPeptide, Accelerating Multi-Modality Strategy And Expanding Global Network Across U.S., Europe, And India 7/19/2026

    Samsung Biologics (KRX: 207940.KS) today announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG ("PolyPeptide") (ISIN CH1110760852, ticker symbol: PPGN), a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).

  7. OXB Selected As GMP Manufacturing Partner To Support Manufacturing Of Plowshare Therapies' AAV Gene Therapy Programme 7/17/2026

    OXB, a global quality and innovation-led cell and gene therapy CDMO, today announces it has signed an agreement with Plowshare Therapies (“Plowshare”), a biotechnology company developing gene therapies for rare genetic diseases.

  8. Mabion And Krisan Biotech Sign Agreement To Strengthen Next-Generation ADC Services 7/17/2026

    The agreement was signed during BIO Asia–Taiwan by Rongjin Lin, Chairman of KriSan Biotech, and Gregor Kawaletz, CEO of Mabion, in the presence of representatives of Poland’s Ministry of Foreign Affairs and Taiwan’s Ministry of Economic Affairs.

  9. Callan JMB And Alabama State University Announce Strategic Partnership To Advance U.S. Pharmaceutical Manufacturing And Supply Chain Resilience 7/16/2026

    Callan JMB Inc. (NASDAQ: CJMB) ("Callan JMB" or the "Company"), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced a strategic partnership with Alabama State University (ASU) to support the development of an integrated pharmaceutical manufacturing ecosystem designed to strengthen domestic pharmaceutical production, enhance supply chain resilience, advance workforce development, and improve national medical preparedness.

  10. Compvide Announces Strategic Collaboration With OpZira To Accelerate Growth And Advance The CIMED Platform 7/16/2026

    Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZira, Inc. to support the company’s continued growth and accelerate development of its proprietary CIMED platform.